Woodline Partners LP Madrigal Pharmaceuticals, Inc. Transaction History
Woodline Partners LP
- $11 Billion
- Q3 2024
A detailed history of Woodline Partners LP transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 147,090 shares of MDGL stock, worth $45.4 Million. This represents 0.28% of its overall portfolio holdings.
Number of Shares
147,090
Previous 138,309
6.35%
Holding current value
$45.4 Million
Previous $38.7 Million
19.44%
% of portfolio
0.28%
Previous 0.39%
Shares
7 transactions
Others Institutions Holding MDGL
# of Institutions
297Shares Held
22MCall Options Held
819KPut Options Held
640K-
Janus Henderson Group PLC London, X02.48MShares$764 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$630 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$626 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$615 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$609 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.28B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...